the history of Zopiclone

Zopiclone was first developed and introduced in 1986 by Rhône-Poulenc SA, now part of Sanofi-Aventis , the main worldwide manufacturer of the drug. Originally it was promoted as being an improvement on benzodiazepines .

Zopiclone, as traditionally sold worldwide, is a racemic mixture of two stereoisomers , only one of which is active. In 2005, the pharmaceutical company Sepracor of Marlborough, Massachusetts began marketing the active stereoisomer eszopiclone under the name Lunesta in the United States. Zopiclone  is already available off-patent in a number of European countries as well as Brazil and Canada . The es zopiclone  and zopiclone difference is in the dose—the strongest es zopiclone  derivative dosage contains 3 mg of the therapeutic stereoisomer, whereas, the highest  zopiclone  dosage (7.5 mg) contains 3.75 mg of the active stereoisomer.

Read more：Zopiclone online